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Abstract
Background: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic
targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine
whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for
the regulation of mood, cognition and emotion, were differentially altered in these pathologies. Methods:
Using postmortem human brains derived from 2 cohorts, [3H]LY341495 binding to mGluR2/3 and
[3H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort
comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP)
and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had
MDNP, BD, schizophrenia and matched controls (n = 15 per group). Results: No differences in mGluR2/3 or
mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control
group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric
disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations
between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups
(MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD).
Limitations: Replication in larger independent cohorts and medication-naive individuals would strengthen
these findings. Conclusion: Our findings suggest that mGluRs are unaltered in the ACC; however, the
presence of altered receptor function cannot be discounted and requires further investigation. Taken together
with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest
mGluRs may be affected in a brain region-specific manner.
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Introduction
Major depression (MD) is an important cause of disability as 
well as financial and emotional burden worldwide. While tradi-
tionally the monoaminergic system has been implicated in the 
pathophysiology and treatment of MD, evidence from clinical, 
preclinical and postmortem studies are rapidly implicating glu-
tamatergic dysregulation in MD.1 Accordingly, metabotropic 
glutamate receptors (mGluRs), which slowly mediate glutama-
tergic neurotransmission, are promising therapeutic targets for 
the treatment of MD. The challenges, however, in elucidating 
the pathophysiology of MD, and therefore appropriate 
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Background: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression 
(MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate 
cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies. 
Methods: Using postmortem human brains derived from 2 cohorts, [3H]LY341495 binding to mGluR2/3 and [3H]MPEP binding to 
mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with 
psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11–12 per group). The second cohort comprised samples 
from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group). Results: No differences in mGluR2/3 or 
mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Impor-
tantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age- 
related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < –0.575, p < 0.025) and the 
psychotic disorder groups (MDP and schizophrenia: r = –0.765 to –0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD). 
Limitations: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings. Conclusion: 
Our findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted 
and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across 
these disorders, we suggest mGluRs may be affected in a brain region–specific manner.
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treatment strategies, are the heterogeneity of the disorder 
and its association with other psychiatric and mood disor-
ders, such as bipolar disorder (BD) and schizophrenia.
Major depression with psychotic features (psychotic depres-
sion) is classified as a subtype of major depression in DSM-IV. 
As recently discussed by Rothschild,2 psychotic depression is 
associated with BD. Studies have shown that patients with 
psychotic depression had an increased risk for BD compared 
with patients with nonpsychotic depression. In contrast, evi-
dence suggests psychotic depression is distinct from schizo-
phrenia.2 It is necessary to characterize the pathophysiology of 
depression, including its psychotic and nonpsychotic types, 
and determine the differences and similarities between BD and 
schizophrenia, as this has crucial implications for advising the 
use of certain pharmacotherapeutics.
Several lines of evidence suggest the involvement of the 
anterior cingulate cortex (ACC) in the pathophysiology of 
depression. It has critical control over mood, emotion and 
cognition, as proven by bilateral cingulotomy psychosur-
gery, which can relieve depression and some psychiatric 
symptoms.3 Concurrently, reduced glutamate levels have 
been reported in the ACC of patients with depression,4–6 
and this is reflected at the protein level for various markers 
expressed at the glutamatergic synapse.7–9 The involvement 
of glutamatergic dysfunction in depression may be specific 
to this brain region, as 1 group found alterations of various 
postsynaptic glutamatergic proteins (NR1 subunit of the N-
methyl-d-aspartate receptor [NMDAR], postsynaptic den-
sity protein 95 [PSD95] and postsynaptic density protein 93 
[PSD93]) in the ACC, but not in the dorsolateral prefrontal 
cortex (DLPFC), in individuals with depression.7
Metabotropic glutamate receptors,  particularly 
mGluR2/3 and mGluR5, have been identified as novel 
thera peutic targets for mood and psychiatric disorders be-
cause of their ability to modulate glutamatergic neurotrans-
mission.10–12 Whereas mGluR2/3 are predominately presyn-
aptic receptors that inhibit glutamate and γ-aminobutyric 
acid (GABA) release into the synapse,13 mGluR5 are primar-
ily expressed postsynaptically, where they modulate the 
glutamate response, especially in association with the 
 NMDAR.11 In addition to their therapeutic potential, 
mGluRs are also implicated in the pathophysiology of these 
disorders. For example, numerous animal studies demon-
strate that selected mGluRs are affected in animal models of 
depression,14,15 and knockout animals display psychotic 
pheno typic behaviours.11,13 From these studies, it is becom-
ing increasingly clear that there may be opposing actions of 
the glutamatergic system in these disorders, particularly as 
mGluR2/3 and mGluR5 blockade appear to be beneficial 
for the treatment of depression, while potentiation of these 
receptors has preclinical efficacy for the treatment of psych-
osis.1,11,13 Hence, mGluR2/3 and mGluR5 may be differen-
tially involved in the pathophysiology of mood and psy-
chotic disorders.
We sought to determine whether mGluR2/3 and mGluR5 
were altered in the ACC of individuals with MD (in the pres-
ence and absence of psychosis) and the associated patholo-
gies BD and schizophrenia. We studied 2 independent post-
mortem cohorts from the Stanley Medical Research Institute: 
the Stanley Depression Collection, consisting of samples from 
individuals who had MD without psychosis (MDNP), MD 
with psychosis (MDP) and controls, and the Stanley Neuro-
pathology Consortium, consisting of samples from individ-
uals who had diagnoses of MDNP, BD and schizophrenia 
and controls. We measured mGluR2/3 and mGluR5 binding 
in the ACC (Brodmann area [BA] 24) of these samples by in 
situ receptor autoradiography. As the ACC is implicated in 
the emotional and cognitive deficits associated with these 
disorders, the findings from this study have translational im-
plications for novel drugs aimed to treat mood and cognitive 
deficits in patients with these disorders.
Methods
Human postmortem brain samples
Frozen postmortem brain tissue was acquired through the 
Stanley Medical Research Institute. From the Depression Col-
lection, we obtained samples from 24 individuals who had 
MD (MDNP: n = 12; MDP: n = 11) and controls (n = 12) 
matched according to age, postmortem interval (PMI), re-
friger ation interval and brain pH (Table 1). Psychosis could not 
be confirmed in 1 of the MD samples, who was therefore ex-
cluded from  psychosis-specific analyses. From the Neuro-
pathology Consortium, we obtained samples from 60 individ-
uals who had MDNP, BD and schizophrenia and controls (n = 
15 per group), matched for age, sex, race and PMI  (Table 2). 
Detailed clinical and demographic information regarding 
these cohorts have been published previously.16,17 The work 
described in this study was approved by the Human Research 
Ethics Committee at the University of Wollongong and con-
ducted according to their guidelines (HE13/069).
Receptor autoradiography
Frozen coronal sections at the level of the ACC (BA24; 14 µm) 
were mounted onto slides and stored at –80°C until the day 
of the assay. Receptor autoradiography studies were based 
on protocols described previously (mGluR2/3;18,19 
mGluR520,21). Autoradiography exposures were optimized for 
mGluR2/3 and mGluR5 to ensure that each cortical layer 
could be quantified on a linear scale and none of the cortical 
layers with high expression were overexposed. The signal to 
noise ratio of mGluR2/3 and mGluR5 binding in all groups 
assayed were well above the nonspecific control. Two sec-
tions for each individual were analyzed for total binding, and 
adjacent sections were used to determine nonspecific bind-
ing. All experiments were performed blind to diagnoses.
mGluR2/3
Tissue sections were preincubated in a buffer solution contain-
ing 50 mM Tris buffer, 2 mM MgCl2 and 2 mM CaCl2 (pH 7) at 
room temperature for 2 × 10 minutes. Subsequently, slides 
were incubated for 60 minutes at room temperature in buffer 
solution containing 50 nM [3H]LY341495 (specific mGluR2/3 
agonist; specific activity 40 Ci/mmol; American Radiolabelled 
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Chemicals). To determine nonspecific binding, adjacent sec-
tions were additionally incubated with 50 nM [3H]LY341495 
and 0.01 mM DCG-IV (specific mGluR2/3 agonist; Sigma). Af-
ter incubation, the slides were washed in 4°C washing buffer 
(50 mM Tris buffer, pH 7) for 2 × 30 seconds and 1 × 1 minute. 
This protocol favours mGluR2 over mGluR3 binding.19
mGluR5
Tissue sections were preincubated for 15 minutes at room 
temperature in 50 mM TrisNaCl (pH 7.5). Slides were then 
incubated in solution containing 10 nM [3H]MPEP (specific 
mGluR5 antagonist; specific activity 60 Ci/mmol; American 
Radiolabelled Chemicals) and 50 mM TrisNaCl for 90 min-
utes at room temperature. Adjacent sections were incubated 
in the same solution with the addition of 10 µM unlabelled 
MPEP (Sigma) to determine nonspecific binding. Slides were 
washed in 4°C TrisNaCl (pH 7.5) for 2 × 3 minutes and 
briefly dipped in 4°C MilliQ-water.
Imaging and quantification
Together with [3H] microscale autoradiographic standards 
(Amersham Biosciences), sections were exposed to tritium 
sensitive Kodak Biomax MR film (Kodak) for 10 weeks. Films 
were developed using the AGFA CP1000 film developer 
(Agfa-Gavaert N.V.), scanned using a GS800 densitometer 
(BioRad) and analyzed using Multi-Analyst software (Bio-
Rad). Quantification was performed blind to diagnoses. 
 Radioligand binding signals were expressed in counts per 
minute (cpm)/mm2 and, with the use of standards and the 
specific activities of the respective radioligands, were con-
verted to fmol/mg tissue equivalents.
Statistical analysis
As data were normally distributed across both cohorts, we used 
parametric tests. No data points were identified as outliers (± 2 
Table 1: Cohort demographic and clinical descriptives of tissue sample donors within the Depression Collection
Group; mean (range)*
Descriptive Control MD (total) MDP MDNP
No. of patient donors 12 24 11 12
Age at death, yr 46.8 (24–62) 42.2 (24–63) 39.6 (28–63) 42.8 (24–56)
Illness duration, yr — 11.7 (0.1–31) 11 (3–21) 12.3 (0.1–31)
Age at illness onset, yr — 29.7 (13–45) 28.6 (13–39) 30.5 (14–45)
Sex, male:female 8:4 13:11 5:6 7:5
PMI, h 25.3 (9–65) 29.6 (13–65) 33.1 (19–52) 23.6 (13–38)
Refrigeration, h† 7.42 (3–18) 7.96 (1–31) 7.18 (1–14) 8 (2–31)
pH 6.64 (6.31–6.57) 6.6 (6.3–6.9) 6.6 (6.3–6.74) 6.7 (6.52–6.9)
Hemisphere, right:left 6:6 15:9 8:3 7:5
Antipsychotics‡ 0 12 9 3
Fluphenazine equivalents — 2 242 (100–6 500) 2 533 (100–6 500) 1 367 (100–3 000)
MD = major depression; MDNP = major depression without psychosis; MDP = major depression with psychosis; PMI = postmortem interval. 
*Unless otherwise indicated.  
†Values refer to the mean interval between patient death and refrigeration of the body at the medical examiner’s office.  
‡Number of patients with a prescription for antipsychotics at the time of death.
Table 2: Cohort demographic and clinical descriptives of tissue sample donors within the Neuropathology 
Consortium
Group; mean (range)*
Descriptive Control MD Bipolar disorder Schizophrenia
No. of patient donors 15 15 15 15
Age at death, yr 48.1 (29–68) 46.5 (30–65) 42.3 (25–61) 44.2 (25–62)
Illness duration, yr — 12.6 (1–42) 20.13 (6–43) 21.3 (5–45)
Age at illness onset, yr — 33.9 (11–54) 21.5 (7–39) 23.2 (13–42)
Sex, male:female 9:6 9:6 9:6 9:6
PMI, h 23.7 (8–42) 27.5 (7–47) 32.5 (13–62) 33.7 (12–61)
FST, d 338.27 (31–774) 434 (86–931) 620 (224–836) 621.13 (68–938)
pH 6.3 (5.8–6.6) 6.2 (5.6–6.5) 6.2 (5.8–6.5) 6.1 (5.8–6.6)
Hemisphere, right:left 7:8 6:9 8:7 6:9
Antipsychotics† 0 0 12 14
Fluphenazine equivalents — — 26 033 (200–60 000) 56 000 (1 000–2 000)
FST = freezer storage time; MD = major depression; PMI = postmortem interval. 
*Unless otherwise indicated.  
†Number of patients with a prescription for antipsychotics at the time of death.
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standard deviations). The depression collection and the neuro-
pathology consortium were analyzed separately. We used an-
aly sis of variance (ANOVA) followed by a Tukey post hoc test 
to compare differences in mGluR2/3 and mGluR5 binding be-
tween the diagnoses in the 2 cohorts (i.e., MDNP, MDP v. con-
trol and MDNP, BD, schizophrenia and control). Subsequently, 
we completed Pearson correlations to determine any influence 
of continuous variables on the data. We then carried out analy-
ses of covariance (ANCOVAs) in which we compared binding 
values between the diagnostic groups in the 2 cohorts, control-
ling for variables that significantly correlated with the data. Sta-
tistical analyses were performed using SPSS software version 
19.0. We considered results to be significant at p < 0.05, and data 
are presented as means ± standard errors of the mean (SEM).
The Stanley Neuropathology Consortium Integrative Database
The Stanley Neuropathology Consortium Integrative Database 
(SNCID; http://sncid.stanleyresearch.org)22 includes 1762 patho-
logical markers measured in 12 different brain regions by the 
Neuropathology Consortium. In line with the hypotheses of the 
present study, we sought to determine if there were associations 
between our measures of mGluR2/3 and mGluR5 and measures 
of other glutamate-related proteins, specifically within the cingu-
late cortex. Exploratory correlation analyses of glutamatergic 
markers (various measures of NMDAR, 2-amino-3-(3-hydroxy-
5-methylisoxazol-4-yl propionate receptor [AMPAR] and kainate 
receptors) and signalling partners (PSD95, brain-derived neuro-
trophic factor [BDNF] and protein kinase C [PKC]) that have pre-
viously been measured in the cingulate cortex (BA not specified) 
was performed using the SNCID as previously described.22 We 
used a nonparametric method (Spearman correlation) to mini-
mize effects caused by differences in units and/or distribution 
patterns.23 All 60 individuals were included, and significance 
was set at p < 0.05. Detailed information regarding the measure-
ment and experimental protocol for each marker is available on 
the SNCID database (http://sncid.stanleyresearch.org).
Results
Distribution
We found that mGluR2/3 ([3H]LY341495) and mGluR5 ([3H]
MPEP) binding were highly expressed in the cortical areas of 
brain slices across the 2 cohorts (Fig. 1). Whereas mGluR5 
binding was homogeneously distributed across all cortical 
layers, mGluR2/3 binding showed pronounced layer differ-
ences; the superficial one-third of the cortex had significantly 
higher binding than the lower layers (p < 0.001) and was ana-
lyzed accordingly.
Fig. 1: Representative receptor autoradiographs of mGluR2/3 [3H]LY341495 and mGluR5 [3H]MPEP binding from the anterior cingulate cortex 
of samples from the (A) Stanley Depression Collection (control, major depression with psychosis, major depression without psychosis) and the 
(B) Stanley Neuropathology Consortium (control, major depression, bipolar disorder and schizophrenia). A representative nonspecific binding 
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Depression Collection
Analysis of demographic and clinical data
Mean pH, age at death, PMI and brain weight did not differ 
among the MDNP, MDP and control groups (F = 0.054–
3.171, all p > 0.05). Excluding controls, further analyses re-
vealed no significant differences between diagnoses (MDNP 
v. MDP) for age of onset (t21 = –0.379, p = 0.71) or illness dur-
ation (t21 = –0.417, p = 0.68). Individuals in the MDNP and 
MDP groups were exposed to antipsychotic medication 
(measured as fluphenazine equivalent units), although aver-
age estimated lifetime exposure did not differ significantly 
between the groups (3 in the MDNP group v. 9 in the MDP 
group, t10 = 0.940, p = 0.37). Quantitative antidepressant and 
mood stabilizer medication histories were not available.
Diagnosis-related effects
One-way ANOVA revealed no significant diagnostic altera-
tions in mGluR2/3 (total: F2,32 = 0.306, p = 0.74; upper: F2,32 = 
1.502, p = 0.24; lower: F2,32 = 0.338, p = 0.72) or mGluR5 (F2,32 = 
0.074, p = 0.93) comparing the MDP, MDNP and control 
groups (Fig. 2). Subsequently, we performed ANCOVAs to 
control for age at death, brain pH, refrigeration interval, 
brain weight and PMI; however, significance was un-
changed for mGluR2/3 (total: F2,27 = 0.934, p = 0.43; upper: 
F2,27 = 0.761, p = 0.72; lower: F2,27 = 0.025, p = 0.98) or mGluR5 
(F2,27 = 1.010, p = 0.46). In addition, we performed an in-
dependent t test to compare all individuals with depression 
(n = 24) and controls (n = 12). No significance was seen for 
either mGluR2/3 (total: t34 = –0.009, p = 0.99; upper: t34 = 
–0.576, p = 0.57; lower: t34 = 0.693, p = 0.49) or mGluR5 (t34 = 
–0.106, p = 0.92).
Effects of demographic and clinical variables
Pearson correlations for continuous variables (pH, age at 
death, PMI, refrigeration interval, brain weight, age at dis-
ease onset, duration of illness and lifetime fluphenazine 
equivalents) are presented in Table 3 and in the Appendix, 
Table S1, available at jpn.ca. Age at death was consistently 
associated with mGluR2/3 binding in the control group 
 (total: r = –0.551, p = 0.06; upper: r = –0.747, p = 0.005; lower: 
r = –0.134; p = 0.94) and in the MDP group (total: r = –0.765, 
p = 0.006; upper: r = –0.748, p = 0.008; lower: r = –0.692, p = 
0.018) but not in the MDNP group (total: r = –0.371, p = 
–0.24; upper: r = –0.383, p = 0.22; lower: r = –0.335, p = 0.29). 
Age at death correlated positively with mGluR5 in the 
MDNP group (r = 0.587, p = 0.045) but not in the MDP 
group (r = 0.551, p = 0.08) or the control group (r = 0.023, p = 
0.94; Table 3).
Overall, there was no effect of lifetime antipsychotic ex-
posure on total or lower mGluR2/3 (total: r = –0.289, p = 
0.19; lower: r = –0.047, p = 0.84) or mGluR5 (r = 0.005, p = 
0.98) in all individuals who had MD (MDNP and MDP), but 
we observed a negative association with mGluR2/3, specif-
ically in the upper layer (r = –0.460, p = 0.031). Power for the 
subgroups was notably low (MDNP: n = 3; MDP: n = 9) and 
was therefore not reported (Table 3).
Fig. 2: Normalized (A) mGluR2/3 [3H]LY341495 and (B) mGluR5 
[3H]MPEP binding density (as measured in fmol/mg tissue) in the 
anterior cingulate cortex of control (CT; diamonds = Depression 
Collection; solid circles = Neuropathology Consortium), major de-
pression with psychosis (MDP; hollow circles), major depression 
without psychosis (MDNP; Depression Collection = hollow squares; 
Neuropathology Consortium = upward arrowheads), bipolar disor-
der (BD; downward arrowheads), and schizophrenia (SZ; solid 
squares) groups. mGluR2/3 and mGluR5 binding densities were 
not altered or differentially expressed in the anterior cingulate cor-
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Neuropathology Consortium
Analysis of demographic and clinical data
Mean pH, age at death, PMI and brain weight did not differ 
among the MDNP, BD, schizophrenia and control groups (F = 
0.420–1.857, all p > 0.147). However, freezer storage time was 
significantly greater in the BD group (281.73 d longer, p = 0.010) 
and the schizophrenia group (282.86 d longer, p = 0.009) than 
the control group. Excluding controls, further ANOVAs and 
post hoc tests revealed significant differences between 
 diagnoses, with the MDNP group having a mean age at onset 
that was 10.73 years older than the schizophrenia group (p = 
0.016) and 12.46 years older than the BD group (p = 0.005). Ill-
ness duration also approached significance, being 8.63 years lon-
ger in the schizophrenia group than in the MDNP group (p = 
0.08). Of the patients who had been exposed to antipsychotic 
medication (12 in the BD group and 14 in the schizophrenia 
group), lifetime antipsychotic exposure did not differ between 
the groups (t24 = –1.557, p = 0.13). Quantitative antidepressant 
and mood stabilizer medication histories were not available.
Diagnosis-related effects
One-way ANOVA revealed no significant diagnostic altera-
tions in mGluR2/3 (overall: F3,56 = 1.387, p = 0.26; upper: F3,56 = 
1.586, p = 0.20; lower: F3,56 = 0.847, p = 0.47) or mGluR5 (F3,56 = 
0.541, p = 0.66) binding densities in the MDNP, BD and 
schizophrenia groups compared with the control group 
(Fig. 2). The ANCOVA controlling for age at death, brain pH, 
brain weight, freezer storage time and PMI confirmed this 
finding for both mGluR2/3 (total: F3,51 = 0.934, p = 0.43; upper: 
F3,51 = 0.761, p = 0.52; lower: F3,51 = 0.818, p = 0.49 and mGluR5 
(F3,51 = 1.010, p = 0.40). As age at disease onset, illness dura-
tion and lifetime fluphenazine equivalents were observed to 
correlate with binding (Table 4 and Appendix, Table S1), we 
performed additional ANCOVAs excluding control samples. 
The data remained nonsignificant for both mGluR2/3 (total: 
F2,35 = 0.998; p = 0.38; upper: F2,35 = 1.203; p = 0.31; lower: F2,35 = 
0.497, p = 0.61) and mGluR5 (F2,35 = 0.382, p = 0.69), suggesting 
no significant difference in mGluR2/3 and mGluR5 binding 
among the MDNP, BD and schizophrenia groups.
Effects of demographic and clinical variables
Pearson correlations for mGluR2/3 and mGluR5 with con-
tinuous variables (pH, age at death, PMI, freezer storage 
time, brain weight, age at disease onset, duration of illness, 
and lifetime fluphenazine equivalents) are presented in Table 
4 and in the Appendix, Table S1. Various correlations for pH, 
brain weight, PMI and freezer storage time were observed 
across the diagnostic groups; these were accounted for by 
ANCOVA and did not affect the diagnostic findings.
Consistent with our results in the Depression Collection, 
age at death had a significant negative effect on mGluR2/3 
Table 3: Pearson correlations for variables influencing mGluR2/3 and mGluR5 binding densities in 
the anterior cingulate cortex within diagnostic groups of the Depression Collection
Diagnosis; variable Age at death Fluphenazine equivalent
All samples, n = 36
mGluR2/3 total r = –0.551 p < 0.001 — —
mGluR2/3 upper r = –0.569 p < 0.001 — —
mGluR2/3 lower r = –0.403 p = 0.015 — —
mGluR5 total r = 0.359 p = 0.032 — —
Controls, n = 12
mGluR2/3 total r = –0.551 p = 0.06 — —
mGluR2/3 upper r = –0.747 p = 0.005 — —
mGluR2/3 lower r = –0.134 p = 0.68 — —
mGluR5 total r = 0.023 p = 0.94 — —
Major Depression, all samples; n = 24
mGluR2/3 total r = –0.570 p = 0.004 r = –0.289* p = 0.19*
mGluR2/3 upper r = –0.507 p = 0.011 r = –0.460* p = 0.031*
mGluR2/3 lower r = –0.529 p = 0.008 r = –0.047* p = 0.84*
mGluR5 total r = 0.545 p = 0.006 r = –0.005* p = 0.98*
Major Depression, with psychosis; n = 11
mGluR2/3 total r = –0.765 p = 0.006 — —
mGluR2/3 upper r = –0.748 p = 0.008 — —
mGluR2/3 lower r = –0.692 p = 0.018 — —
mGluR5 total r = 0.551 p = 0.08 — —
Major Depression, without psychosis; n = 12
mGluR2/3 total r = –0.371 p = 0.24 — —
mGluR2/3 upper r = –0.383 p = 0.22 — —
mGluR2/3 lower r = –0.335 p = 0.29 — —
mGluR5 total r = 0.587 p = 0.045 — —
*n = 12.
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binding in the control group (total: r = –0.695, p = 0.004; up-
per: r = –0.666, p = 0.007; lower: r = –0.575, p = 0.025) and in 
the schizophrenia group (total: r = –0.528, p = 0.043; upper: 
r = –0.458, p = 0.09; lower: r = –0.515, p = 0.049) groups, but 
not in the MDNP or BD groups. Age at death displayed a 
borderline significant correlation with mGluR5 in the schizo-
phrenia group (r = 0.505, p = 0.06) but not in the MDNP, BD 
or control groups. Illness duration also significantly and neg-
atively correlated in the schizophrenia group for mGluR2/3 
(total: r = –0.697, p = 0.004; upper: r = –0.734, p = 0.002; lower 
r = –0.539, p = 0.038), although this correlation was not seen 
with mGluR5. Although lifetime antipsychotic medication 
did not differ between the schizophrenia and BD diagnostic 
groups, a significant negative correlation with mGluR2/3 
was observed, specifically in the BD group (Table 4).
Correlations with glutamatergic markers and signalling 
partners in the SNCID
Explorative Spearman correlations with the data from the 
present study and those from previous studies (available in 
the SNCID) are presented in the Appendix, Table S2. Various 
significant associations were observed, both overall and in in-
dividual pathologies, between mGluR2/3 and mGluR5 with 
measures of NMDAR, AMPAR and kainate receptors as well 
as signalling partners PSD95, PKC and BDNF.
Discussion
The mGluR2/3 and mGluR5 receptors are targets of new 
therapeutic approaches for psychiatric conditions, including 
MD, BD and schizophrenia. Furthermore, animal studies 
have suggested the involvement of these receptors in the 
pathophysiologies of these disorders.1,11 In light of this, we 
have examined binding to mGluR2/3 and mGluR5 in post-
mortem brains, specifically the ACC, of individuals with MD 
(MDP, MDNP), BD and schizophrenia and compared them 
to matched controls. In particular, we chose the receptor 
binding technique and radioligands that target the same 
binding sites as novel drugs currently under development to 
determine how drugs targeting these receptor sites may be 
affected in the patient. We report no significant diagnostic al-
terations of mGluR2/3 binding or mGluR5 binding in the 
ACC in individuals with these pathologies.
Unaltered levels of mGluR2/3 and mGluR5 in depression 
(with or without psychosis)
mGluR2/3 and mGluR5 are prominent prospective targets 
in the treatment of mood disorders, as both clinical and pre-
clinical studies have shown antidepressant properties of 
 antagonists or negative allosteric modulators targeted at 
Table 4: Pearson correlations for variables influencing mGluR2/3 and mGluR5 binding 
densities in the anterior cingulate cortex within diagnostic groups of the Neuropathology 
Consortium.
Diagnosis; variable Age at death Fluphenazine equivalent
All samples, n = 60
mGluR2/3 total r = –0.410 p = 0.001 — —
mGluR2/3 upper r = –0.464 p < 0.001 — —
mGluR2/3 lower r = –0.273 p = 0.035 — —
mGluR5 total r = 0.087 p = 0.51 — —
Controls, n = 15
mGluR2/3 total r = –0.695 p = 0.004 — —
mGluR2/3 upper r = –0.666 p = 0.007 — —
mGluR2/3 lower r = –0.575 p = 0.025 — —
mGluR5 total r = –0.305 p = 0.27 — —
Major depression, n = 15
mGluR2/3 total r = –0.258 p = 0.35 — —
mGluR2/3 upper r = –0.355 p = 0.19 — —
mGluR2/3 lower r < 0.001 p = 0.10 — —
mGluR5 total r = –0.453 p = 0.09 — —
Bipolar disorder, n = 15
mGluR2/3 total r = –0.045 p = 0.87 r = –0.554 p = 0.032
mGluR2/3 upper r = –0.286 p = 0.30 r = –0.525 p = 0.045
mGluR2/3 lower r = 0.170 p = 0.55 r = –0.482 p = 0.07
mGluR5 total r = 0.023 p = 0.93 r = –0.131 p = 0.64
Schizophrenia, n = 15
mGluR2/3 total r = –0.528 p = 0.043 r = –0.109 p = 0.70
mGluR2/3 upper r = –0.458 p = 0.09 r = 0.016 p = 0.96
mGluR2/3 lower r = –0.515 p = 0.049 r = –0.225 p = 0.42
mGluR5 total r = 0.505 p = 0.06 r = 0.477 p = 0.07
Matosin et al.
414 J Psychiatry Neurosci 2014;39(6)
mGluR2/3 and mGluR5.1,12 To our knowledge, we are the 
first to report that neither mGluR2/3 nor mGluR5 binding 
levels are altered in the ACC of individuals with MD, in the 
presence (MDP) or absence (MDNP) of psychosis. Our re-
sults are in line with a previous study reporting unaltered 
mGluR2 and mGluR3 gene expression in the postmortem 
ACC of individuals with MD.9 We found no other studies 
that have investigated mGluRs in the ACC in individuals 
with depression. In other brain regions of depressed pa-
tients, an increase in mGluR2/324 and reduction of mGluR5 
protein in the prefrontal cortex (BA10) have been reported, 
together with reduced (in vivo) prefrontal cortical mGluR5 
binding25 and increased mGluR5 gene expression in the lo-
cus coeruleus.26 Although it is difficult to draw conclusions 
from only a small number of studies, the inconsistencies be-
tween these findings highlight the inherent regional differ-
ences in mGluRs in the pathophysiology of MD as well as 
the importance of considering psychiatric subclass. These 
prior studies have an important limitation in that they do 
not distinguish between MDP and MDNP, particularly 
since differential proteome profiles have been recently re-
ported, specifically between MDNP and MDP.17
mGluR2/3 and mGluR5 binding does not differ in BD and 
schizophrenia compared with depression
In line with depression with and without psychosis we report 
that mGluR2/3 and mGluR5 binding density are unaltered in 
the ACC in individuals with schizophrenia and BD. While 
mGluR binding, to our knowledge, has not previously been 
measured in individuals with BD, studies in the prefrontal 
cortex, thalamus and striatum of individuals with schizo-
phrenia have likewise reported no change in mGluR2/319,27–30 
or mGluR511,21 (binding, protein or mRNA). Our findings 
highlight that in the ACC there are no distinct differences be-
tween the overlapping diagnoses of MDNP, MDP, schizo-
phrenia and BD with regards to binding to mGluR2/3 and 
mGluR5. This suggests that novel pharmacological modula-
tors of mGluR2/3 and mGluR5 may have unhindered bind-
ing sites in all these disorders.
It should, however, be noted that there may be wider dys-
regulations in mGluR2/3 and mGluR5 function that were not 
measured within the scope of our study or that there may be 
alterations in other mGluR subtypes dependent on specific 
brain regions.12 For example, Volk and colleagues31 found re-
ductions in mGluR1a mRNA, but not mGluR5, in the pre-
frontal cortex (BA9 and BA42) of patients with schizophrenia. 
Conversely another more recent study found mGluR5 
mRNA and protein to be reduced specifically in BA9 and the 
lateral cerebellum in individuals with schizophrenia.32 These 
examples highlight the heterogeneity and intricacies of spec-
trum disorders such as schizophrenia.33
Current and novel pharmacotherapy implications
In the present study we found evidence of a negative associa-
tion between mGluR2/3 binding and antipsychotic dose, 
specifically in individuals with BD and MD, but not in those 
with schizophrenia. Previous postmortem studies have re-
ported no association between antipsychotic dose and 
mGluR2/319,27,28 or mGluR5,21 specifically in patients with 
schizophrenia. Animal studies have reported no effect of anti-
psychotics on mGluR2/334 or mGluR5 binding.21 The effects of 
antidepressants have not been as well studied, and while reli-
able quantitative lifetime antidepressant drug history was not 
available in the present study, our previous work found no as-
sociation of antidepressant history and mGluR5 binding and 
protein in the DLPFC in individuals with schizophrenia.21 
 Deschwanden and colleagues,25 however, found that anti-
depressant treatment may reduce mGluR5 binding specifically 
in the precentral gyrus of antemortem patients with MD. Ani-
mal studies have shown that tricyclic antidepressant treatment 
significantly increases mGluR2/335 and mGluR5a36 protein in 
the rat hippocampus, although another study found that total 
mGluR5 protein levels were unaltered.35 To our knowledge, 
there are no prior studies on antidepressant effects specifically 
in the ACC to shed light on these findings; therefore, further 
investigation is required.
The mGluR-targeted modulators have shown promising 
antipsychotic and antidepressant therapeutic potential in pre-
clinical and clinical studies. Orthosteric and allosteric modula-
tors of mGluRs target binding sites on either the N-terminus 
(mGluR2/3) or transmembrane (mGluR5) domain, respect-
ively.1,11,13,37 These orthosteric and allosteric binding sites 
were the same targets of the radioligands used in the present 
study. As we report that these binding sites are not altered in 
the ACC in psychopathology, mGluR2/3 and mGluR5 may 
be unimpeded targets for novel antidepressant and antipsy-
chotic intervention. As results from recent clinical trials with 
mGluR modulators indicated that specific single nucleotide 
polymorphisms (SNPs) were associated with treatment re-
sponse,38 further study into these same binding sites in indi-
viduals with these SNPs would be of value. In addition, we 
consistently found a negative correlation between mGluR2/3 
binding and age in the control, schizophrenia and MDP 
groups, with no association in the MDNP and BD groups. 
Age-related differences in treatment approaches remain an 
issue,39 and our findings suggest there may be differential 
treatment responses to these novel therapeutics depending 
on the pathology and age of the patient.
Association of mGluRs with markers in the wider  
glutamatergic system
In addition to the metabotropic group of glutamate receptors, 
glutamate signalling is also transduced through the ionotropic 
glutamate receptors NMDAR, AMPAR and kainate receptors. 
The NMDAR and AMPAR receptors are of particular interest as 
they signal closely with mGluR511 and mGluR2/3,12 respect-
ively, and novel mGluR2/3- and 5- based drugs are proposed to 
exert their therapeutic effects, at least partially, through their in-
fluence on NMDAR and AMPAR.11,12 In addition, PSD-95 is a 
key signalling partner of mGluR5 as it physically and function-
ally links it to NMDAR in the postsynapse, while PKC and 
BDNF are downstream signalling effectors of mGluR5/ 
NMDAR signalling.11 We explored the association of mGluR2/3 
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and mGluR5 measured in the present study in relation to meas-
ures of these glutamatergic markers as available on the SNCID. 
We chose a total of 29 markers representing glutamatergic 
markers and signalling partners within the cingulate cortex.
As expected, we observed a number of differential associ-
ations between mGluR2/3, mGluR5 and these glutamater-
gic markers and signalling partners (see the Appendix, 
 Table S2). Many of these associations were specific to 1 of 
the 3 psychiatric disorders examined, indicating that there 
may be differential associations in the pathophysiologies of 
these disorders. However, although correlation analyses are 
useful to identify associations between markers, they do not 
indicate causality and must be treated as exploratory. These 
associations may provide direction for future studies aim-
ing to distinguish pathological differences between these 
psychiatric disorders.
Limitations
While our findings suggest possible age-related differences 
between the psychotic and mood components, further analy-
sis in a larger postmortem cohort is required to support this 
notion. In addition, further studies are required to determine 
if mGluR2/3 or mGluR5 function or downstream signalling 
are altered in these pathologies. It should be noted that de-
spite no pathological alteration of mGluR2/3 and mGluR5 
binding sites in the present study, the ACC remains highly 
involved in these pathologies as alterations of various neuro-
transmitters and their associated receptors have been 
 reported in this brain region.3,7,40–42 Although our study pro-
vides valuable information on these binding sites in psychi-
atric pathology, additional studies examining binding specif-
ically to membranous mGluR2/3 and mGluR5 and the 
affinity of novel mGluR2/3- and mGluR5-targeting drugs for 
these receptors in psychiatric disorders will provide valuable 
insight into the effectiveness of these drugs in the patient.33
One confound of postmortem studies in neuropsychiatric 
disorders, is the presence of comorbid substance abuse, espe-
cially alcohol and drug abuse, or at least substantially higher 
alcohol43 and illicit drug44 intake in patients with psychiatric 
disorders. While reliable quantitative patient histories were 
not available in the present study, mGluR1/5 densities in the 
prefrontal cortex may be affected by alcohol,45 and mGluR2 
gene expression was reported to be reduced in the ACC of pa-
tients with alcohol addiction.46 Furthermore, there is a growing 
body of evidence suggesting that mGluRs may be involved in 
drug and alcohol addiction disorders.47 Therefore, the molecu-
lar effects of alcohol and drug use should be considered when 
interpreting the present and prior/future studies.
Conclusion
To our knowledge, we have assessed for the first time 
mGluR2/3 and mGluR5 binding capacity in the ACC in indi-
viduals with MD with and without psychosis as well as those 
with BD and schizophrenia. While we provide evidence that 
age is differentially associated with mGluR2/3 binding in indi-
viduals with psychotic and mood disorders, we found no al-
terations in mGluR2/3 or mGluR5 binding compared with 
controls or between any studied pathological state. This sug-
gests that mGluR2/3- and mGluR5-based therapeutics used to 
treat emotional and cognitive deficits may have unhindered 
binding capacity in these pathological states. Future studies 
may extend on this work by investigating mGluR protein/
mRNA expression and their association with other mGluRs, 
specifically in the ACC and other brain limbic structures; this 
would increase our understanding of the role of mGluRs in the 
neuropathologies of psychiatric disease and elucidate their 
treatment potential.
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